Tocilizumab in the treatment of adult rheumatoid arthritis

被引：15

作者：

Sanmarti, Raimon ^{[1
]}

Ruiz-Esquide, Virginia ^{[1
]}

Bastida, Carla ^{[2
]}

Soy, Dolor ^{[2
]}

机构：

[1] Hosp Clin Barcelona, Rheumatol Serv, Arthritis Unit, Barcelona, Catalonia, Spain

[2] Hosp Clin Barcelona, Pharm Serv, Barcelona, Catalonia, Spain

来源：

IMMUNOTHERAPY | 2018年 / 10卷 / 06期

关键词：

biologic DMARDs; IL-6; receptor; rheumatoid arthritis; tocilizumab; MODIFYING ANTIRHEUMATIC DRUGS; NECROSIS-FACTOR INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; ROUTINE CLINICAL-PRACTICE; PLACEBO-CONTROLLED TRIAL; BODY-MASS INDEX; DOUBLE-BLIND; IL-6; RECEPTOR; SUBCUTANEOUS TOCILIZUMAB;

D O I：

10.2217/imt-2017-0173

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Rheumatoid arthritis (RA) is the most prevalent immune-mediated chronic rheumatic disease and is associated with joint destruction and disability. Therapeutic strategies, including biological disease-modifying antirheumatic drugs (bDMARDs) have improved the prognosis and quality of life of RA patients. Tocilizumab (TCZ) is a humanized monoclonal antibody against IL-6 receptor licensed in 2009 that has demonstrated clinical efficacy in various adult RA populations. RA management guidelines and recommendations consider TCZ as one of the bDMARDS indicated after methotrexate or other conventional synthetic DMARDs and/or TNF inhibitors failure in adult RA. Of particular interest is the demonstration of its effectiveness in monotherapy in comparison with other bDMARDs. Recent observational studies have shown good results for the safety profile of TCZ with no new alert signals.

引用

页码：447 / 464

页数：18

共 103 条

[1] Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in PatientsWith Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA [J].

Abdallah, Hisham ;

Hsu, Joy C. ;

Lu, Peng ;

Fettner, Scott ;

Zhang, Xiaoping ;

Douglass, Wendy ;

Bao, Min ;

Rowell, Lucy ;

Burmester, Gerd R. ;

Kivitz, Alan .

JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (04) :459-468

[2] Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice [J].

Backhaus, Marina ;

Kaufmann, Joerg ;

Richter, Constanze ;

Wassenberg, Siegfried ;

Roske, Anne-Eve ;

Hellmann, Peter ;

Gaubitz, Markus .

CLINICAL RHEUMATOLOGY, 2015, 34 (04) :673-681

[3] Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study [J].

Balsa, Alejandro ;

Tovar Beltran, Juan Victor ;

Caliz Caliz, Rafael ;

Mateo Bernardo, Isabel ;

Garcia-Vicuna, Rosario ;

Rodriguez-Gomez, Manuel ;

Belmonte Serrano, Miguel Angel ;

Marras, Carlos ;

Loza Cortina, Eduardo ;

Perez-Pampin, Eva ;

Vila, Vicente .

RHEUMATOLOGY INTERNATIONAL, 2015, 35 (09) :1525-1534

[4] Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs [J].

Bergman, Gert J. D. ;

Hochberg, Marc C. ;

Boers, Maarten ;

Wintfeld, Neil ;

Kielhorn, Adrian ;

Jansen, Jeroen P. .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 39 (06) :425-441

[5] Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial [J].

Bijlsma, Johannes W. J. ;

Welsing, Paco M. J. ;

Woodworth, Thasia G. ;

Middelink, Leonie M. ;

Petho-Schramm, Attila ;

Bernasconi, Corrado ;

Borm, Michelle E. A. ;

Wortel, Cornelis H. ;

ter Borg, Evert Jan ;

Jahangier, Z. Nazira ;

van der Laan, Willemijn H. ;

Bruyn, George A. W. ;

Baudoin, Paul ;

Wijngaarden, Siska ;

Vos, Petra A. J. M. ;

Bos, Reinhard ;

Starmans, Mirian J. F. ;

Griep, Eduard N. ;

Griep-Wentink, Joanna R. M. ;

Allaart, Cornelia F. ;

Heurkens, Anton H. M. ;

Teitsma, Xavier M. ;

Tekstra, Janneke ;

Marijnissen, Anne Carien A. ;

Lafeber, Floris P. J. ;

Jacobs, Johannes W. G. .

LANCET, 2016, 388 (10042) :343-355

[6] Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA) [J].

Bingham, Clifton O., III ;

Rizzo, Warren ;

Kivitz, Alan ;

Hassanali, Azra ;

Upmanyu, Ruchi ;

Klearman, Micki .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (05) :818-822

[7] Pathways for Bone Loss in Inflammatory Disease [J].

Braun, Tobias ;

Schett, Georg .

CURRENT OSTEOPOROSIS REPORTS, 2012, 10 (02) :101-108

[8] The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[9] Low immunogenicity of tocilizumab in patients with rheumatoid arthritis [J].

Burmester, Gerd R. ;

Choy, Ernest ;

Kivitz, Alan ;

Ogata, Atsushi ;

Bao, Min ;

Nomura, Akira ;

Lacey, Stuart ;

Pei, Jinglan ;

Reiss, William ;

Pethoe-Schramm, Attila ;

Mallalieu, Navita L. ;

Wallace, Thomas ;

Michalska, Margaret ;

Birnboeck, Herbert ;

Stubenrauch, Kay ;

Genovese, Mark C. .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) :1078-1085

[10] Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial [J].

Burmester, Gerd R. ;

Lin, Yong ;

Patel, Rahul ;

van Adelsberg, Janet ;

Mangan, Erin K. ;

Graham, Neil M. H. ;

van Hoogstraten, Hubert ;

Bauer, Deborah ;

Ignacio Vargas, Juan ;

Lee, Eun Bong .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (05) :840-847

← 1 2 3 4 5 6 7 8 9 10 →